Indexing in SciSearch means that articles published in the journal are systematically cataloged, with structured metadata including author names, affiliations, abstracts, and cited references. This infrastructure allows the journal’s output to be discovered through standardized searches, tracked for citation activity, and aggregated into bibliometric analyses. For authors, inclusion in the database ensures that their work is counted in institutional assessments and that citations to their papers are captured in the citation indexes that underpin modern research evaluation.

Alongside the indexing achievement, the journal recorded an Impact Factor of 5.5 in 2022, according to the source announcement. Within the Journal Citation Reports category of Pharmacology and Pharmacy, that figure corresponded to a Q1 quartile ranking, placing the journal 48th out of 278 titles in the category. Quartile rankings divide journals in a category into four groups by citation performance, and Q1 designates the top quarter, a status widely regarded as an indicator of strong relative influence within a field.

The Impact Factor itself is calculated from citations accrued in a given year to items published in the two preceding years, divided by the number of citable items published in that window. A score of 5.5 indicates that, on average, recent articles in the journal were cited more than five times within the measurement period. While bibliometricians caution that the metric reflects aggregate citation behavior rather than the quality of any individual paper, it remains one of the most consulted indicators when researchers choose where to submit manuscripts and when libraries decide which subscriptions to maintain.

For a journal focused on pharmaceutical investigation, the Q1 position in Pharmacology and Pharmacy carries particular weight. The category is crowded and competitive, spanning basic pharmacology, clinical pharmacy practice, drug delivery science, and regulatory science. Ranking 48th of 278 means the journal sits comfortably within the upper tier of a broad and active field, competing for attention with long-established titles that have decades of accumulated citation history.

The timing of the SciSearch indexing in 2021 is significant for the journal’s trajectory. Journals typically need a period of consistent publication and editorial rigor before they are evaluated for Web of Science coverage, and newly indexed titles generally receive their first Impact Factor only after a full citation window has elapsed. The 2022 Impact Factor therefore represents an early but meaningful validation of the journal’s growing footprint in the pharmaceutical sciences literature.

From the perspective of the research community, expanded indexing and strong citation metrics have practical consequences. Manuscript submissions tend to rise as visibility increases, which in turn allows editorial teams to be more selective. Authors in drug delivery, pharmacokinetics, and pharmaceutical formulation often weigh indexing status heavily because funding agencies and promotion committees in many countries explicitly require publications in Web of Science–indexed journals. The journal’s inclusion removes a barrier for authors in those systems and broadens its potential contributor base across Asia, Europe, and the Americas.

Librarians and information scientists also benefit from the development. Abstracting and indexing services create the connective tissue of scholarly communication: without them, discovering relevant articles across thousands of journals would be impractical. Coverage in SciSearch ensures that the journal’s content is integrated into discovery platforms used by universities and industry research groups, supporting systematic reviews, competitor intelligence in pharmaceutical R&D, and citation network analyses that map emerging research fronts in drug development.

The announcement, published through Springer’s journal updates for the Journal of Pharmaceutical Investigation, highlights how indexing and citation performance function as complementary signals. Indexing establishes that a journal meets baseline editorial and technical standards, while the Impact Factor and quartile ranking describe how its published work resonates with the research community. Together, they offer a concise summary of the journal’s standing: a title that has entered the mainstream of indexed pharmacology literature and, within two years, achieved a top-quartile citation profile in its category.

As the pharmaceutical sciences continue to expand, with growing attention to biologics, nanomedicine, and personalized drug delivery, the visibility provided by comprehensive indexing will shape which journals anchor the field’s scholarly record. For the Journal of Pharmaceutical Investigation, the 2021 SciSearch inclusion and the 2022 Impact Factor of 5.5, with its Q1 ranking of 48 out of 278 in Pharmacology and Pharmacy, mark a notable consolidation of its position among the publications that researchers in the discipline consult, cite, and trust.

Subject of Research: Abstracting and indexing of the Journal of Pharmaceutical Investigation in Science Citation Index Expanded and its 2022 Impact Factor of 5.5 with a Q1 ranking in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, Q1 journal, Pharmacology and Pharmacy, Web of Science, pharmaceutical sciences, journal citation metrics, Springer, scholarly publishing

Abstracting and indexing is one of those quiet pieces of scientific infrastructure that most readers never think about, yet it determines nearly everything about how research travels. When a journal is indexed in a major database, every article it publishes is given a standardized bibliographic record, complete with authors, affiliations, keywords, and a persistent identifier, that can be retrieved by search engines, discovery platforms, and citation-tracking systems. Without that record, even excellent research risks becoming effectively invisible, buried in a journal that databases do not scan. Inclusion in the Science Citation Index Expanded, maintained as part of the Web of Science family of databases, is therefore a mark of editorial quality control and a practical guarantee that a journal’s output will be findable by the global research community.

The Science Citation Index Expanded has a long history as one of the core citation indexes in science. It covers thousands of journals across the natural sciences, engineering, medicine, and related disciplines, and its selection process is deliberately selective. Journals are evaluated on publishing standards, editorial rigor, international diversity of authorship and editorial boards, citation behavior, peer-review integrity, and the overall usefulness of the content to the research community. For a journal to be admitted, and then to remain, in the index requires sustained performance against those criteria. The Journal of Pharmaceutical Investigation’s entry into the index in 2021 marked the point at which its articles began accumulating formal citation records in the Web of Science ecosystem, the raw material from which metrics such as the Impact Factor are later computed.

That leads directly to the second and more widely discussed number: the 5.5 Impact Factor recorded for 2022. The Journal Impact Factor, produced annually in the Journal Citation Reports, is calculated by counting citations in a given year to items published in the journal during the two preceding years, then dividing by the number of citable items, typically articles and reviews, published in those same two years. A 2022 Impact Factor of 5.5 therefore reflects the average number of times that 2020 and 2021 articles in the journal were cited during 2022. It is a two-year citation window, which makes the metric sensitive to recent momentum and to fields where citation practices are fast-moving, as pharmaceutical research very much is.

Context matters enormously when interpreting that figure. A raw Impact Factor of 5.5 means little until it is compared against other journals in the same field, which is exactly what the category ranking provides. In Pharmacology and Pharmacy, a broad and heavily populated category with 278 indexed journals, the Journal of Pharmaceutical Investigation ranked 48th, placing it in the top quartile, or Q1. Quartile designations divide each category into four bands, and Q1 status is commonly used by libraries, funding agencies, and university evaluation committees as a shorthand for a journal sitting among the most influential quarter of titles in its discipline. For a journal that only entered the index in 2021, reaching Q1 within roughly two years of eligibility represents a notably rapid climb.

The mechanics behind that climb are worth understanding, because they illustrate how citation dynamics work in pharmaceutical research. Journals in this field benefit from several structural advantages: pharmaceutical science sits at the intersection of chemistry, biology, pharmacology, and clinical medicine, so articles tend to be cited from many neighboring disciplines rather than a single narrow community. Drug delivery technologies, formulation science, pharmacokinetics, and nanomedicine are all areas of intense global activity, and work published in these areas is frequently referenced in patents, review articles, and follow-up experimental studies. A journal that successfully attracts strong submissions in these active areas can accumulate citations quickly, and the two-year Impact Factor window rewards exactly that kind of momentum.

At the same time, the pharmaceutical research community has been vocal in recent years about the limits of single-number metrics, and any reading of the new figures should acknowledge those debates. The Impact Factor does not distinguish between a highly cited review and a routine research article, it can be influenced by a small number of exceptionally cited papers, and it says nothing about the methodological quality or reproducibility of individual studies. Initiatives such as the Declaration on Research Assessment, known as DORA, have urged institutions to move away from journal-level metrics when judging individual researchers, favoring article-level measures and qualitative expert review instead. The Journal of Pharmaceutical Investigation’s Q1 ranking is best understood as one signal among several, indicating broad visibility and citation uptake rather than certifying the quality of any specific paper.

For authors deciding where to submit, indexing status and quartile rankings still carry practical weight. Many national funding bodies and promotion committees maintain lists of acceptable journals built directly on Web of Science indexing and quartile positions, and some require publication in Q1 or Q2 titles for grant eligibility or degree completion. Indexing in the Science Citation Index Expanded also ensures that articles are preserved and discoverable through institutional libraries worldwide, which affects readership and, indirectly, future collaboration opportunities. In this sense, the journal’s documented indexing record and its 2022 metrics function as a form of infrastructure: they lower the friction between a published finding and the researcher who needs it.

What happens next will depend on the journal’s continued editorial performance. Impact Factors are recalculated every year, and quartile boundaries shift as competing journals rise and fall, so the 48th-of-278 position is a snapshot rather than a permanent achievement. Journals that sustain rigorous peer review, publish timely special issues in fast-moving areas such as biologics, drug delivery systems, and personalized pharmacotherapy, and maintain transparent editorial practices tend to hold their positions, while those that do not can slip quickly in a category as crowded as Pharmacology and Pharmacy. For now, the published record is clear: indexed in SciSearch since 2021, an Impact Factor of 5.5 in 2022, and a Q1 ranking within one of pharmacology’s largest and most competitive categories, a combination that firmly establishes the Journal of Pharmaceutical Investigation among the visible and influential outlets for pharmaceutical research.

Subject of Research: Indexing status and 2022 Impact Factor performance of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, Journal Citation Reports, Pharmacology and Pharmacy, Q1 ranking, Web of Science, citation metrics, scholarly publishing, journal ranking

Abstracting and indexing services form the backbone of modern scientific communication. When a journal is accepted into the Science Citation Index Expanded, it means that its published articles are systematically cataloged, metadata is extracted and standardized, and the content becomes discoverable through the Web of Science platform maintained by Clarivate. This process is far more than a bureaucratic formality. Inclusion in a major citation index determines whether researchers around the world can efficiently locate, retrieve, and cite a journal’s content. For pharmaceutical scientists, whose work often spans chemistry, pharmacology, formulation science, and clinical research, discoverability through trusted indexes is essential to ensuring that findings reach the practitioners and regulators who can act upon them.

The Science Citation Index Expanded, originally established as part of the Science Citation Index created by Eugene Garfield in the 1960s, has long served as one of the most selective and influential databases in academic publishing. Journals are admitted only after a rigorous evaluation process that examines editorial rigor, peer-review integrity, regularity of publication, international editorial diversity, and the citation behavior of the published literature. The fact that the Journal of Pharmaceutical Investigation entered SciSearch coverage in 2021 means that its articles published from that year onward are now tracked within the citation network that underpins modern bibliometrics, including the annual Journal Impact Factor calculations.

The Impact Factor itself remains the most widely recognized, and most widely debated, quantitative measure of a journal’s influence. Calculated each year by Clarivate, the metric reflects the average number of citations received in a given year by articles published in the journal during the two preceding years. An Impact Factor of 5.5 for 2022 indicates that, on average, articles published in the journal in 2020 and 2021 were cited 5.5 times in 2022 across the indexed literature. In the highly competitive Pharmacology and Pharmacy category, where hundreds of journals compete for the attention of a global research community, this average places the Journal of Pharmaceutical Investigation in the top tier of its discipline.

The quartile designation adds important context to the raw number. Ranking 48th among 278 journals in Pharmacology and Pharmacy corresponds to the Q1 band, the highest quartile of the category. Quartile rankings are derived by ordering all journals in a category by their Impact Factor and dividing the list into four equal groups. Q1 status is frequently used by research institutions, funding agencies, and university committees as a shorthand marker of journal prestige, influencing decisions about where researchers submit their work, how publications are weighted in hiring and promotion evaluations, and which journals libraries prioritize in their subscriptions. For authors weighing where to publish their pharmaceutical research, a Q1 designation with a 5.5 Impact Factor signals a venue with demonstrated reach and citation performance.

Pharmacology and pharmacy is one of the most densely populated categories in the Web of Science, reflecting the breadth of research that falls under its umbrella. The category encompasses basic pharmacological research into drug receptors and signaling pathways, medicinal chemistry and drug design, pharmacokinetics and drug metabolism, formulation and delivery technologies, clinical pharmacology, and pharmacy practice research. Journals in this space range from highly specialized outlets focused on narrow subfields to broad-spectrum publications that cover the full arc from molecule to medicine. Within this crowded landscape, achieving a position in the upper fifth of the category requires consistent publication of work that other researchers find useful enough to cite, year after year.

The Journal of Pharmaceutical Investigation has built its reputation on content that spans pharmaceutical technology, drug delivery systems, biopharmaceutics, and the clinical investigation of medicines. Its scope reflects the realities of contemporary drug development, where advances increasingly emerge at the boundaries between disciplines. Novel formulations such as lipid nanoparticles, long-acting injectables, and targeted delivery platforms demand expertise that bridges physical pharmacy, materials science, and regulatory science. Similarly, the evaluation of biosimilars, generics, and novel therapeutic modalities requires integration of analytical chemistry, pharmacokinetic modeling, and clinical trial methodology. A journal that serves as a conduit for this interdisciplinary work occupies a valuable position in the scientific ecosystem, and its citation performance suggests that the community recognizes that value.

Indexing in SciSearch also carries practical consequences for the researchers who publish in the journal. Articles included in the Science Citation Index Expanded are assigned digital object identifiers and standardized metadata that feed into institutional research information systems, national assessment exercises, and funder reporting requirements. In many countries, publication in indexed journals is a formal criterion for doctoral degree completion, grant eligibility, and academic advancement. For authors based in the Asia-Pacific region and beyond, where the Journal of Pharmaceutical Investigation has historically maintained strong connections through its publisher and editorial network, the journal’s expanded indexing profile enhances the portability and recognition of their published work across international evaluation systems.

The timing of the journal’s entry into the citation index is also noteworthy. Coverage beginning in 2021 means the journal’s recent publication record has been captured during a period of extraordinary activity in pharmaceutical research. The global pandemic accelerated investment in vaccine technology, antiviral therapeutics, and manufacturing science, while parallel advances in biologics, cell and gene therapies, and digital health technologies reshaped the drug development pipeline. Citation activity across pharmacology surged during this period, and journals positioned at the interface of pharmaceutical formulation and clinical investigation benefited from heightened attention to their subject matter. The 5.5 Impact Factor for 2022 reflects not only the journal’s editorial strategy but also the intensity of scientific exchange in its field during the measurement window.

Looking ahead, the combination of SciSearch indexing and Q1 standing positions the Journal of Pharmaceutical Investigation to attract submissions from a broader international author base and to deepen its role in shaping discourse on pharmaceutical innovation. Metrics are never a complete measure of a journal’s contribution, and the scholarly community continues to debate the appropriate weight given to Impact Factors in research assessment. Nevertheless, the journal’s current profile, indexed from 2021 with an Impact Factor of 5.5 and a Q1 ranking of 48 out of 278 in Pharmacology and Pharmacy, provides an objective snapshot of its standing. For a publication devoted to the investigation of medicines from laboratory bench to patient bedside, the numbers confirm what its readers and contributors have long understood: rigorous pharmaceutical science, when curated and disseminated effectively, earns its place at the center of the global research conversation.

Subject of Research: Indexing and citation metrics of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, SciSearch, Impact Factor, Q1 journal, Pharmacology and Pharmacy, abstracting and indexing, Clarivate, Web of Science, pharmaceutical sciences, journal metrics, drug development

To understand why indexing in Science Citation Index Expanded carries such weight, it helps to consider what the database actually represents. Maintained by Clarivate, the Science Citation Index Expanded is one of the core components of the Web of Science, the citation ecosystem that underpins the Journal Impact Factor, one of the most scrutinized metrics in academic publishing. Journals are not simply admitted to the index; they must pass through a rigorous evaluation process that examines editorial rigor, publishing timeliness, international diversity among authors and editors, citation behavior, and the overall scholarly contribution of the published work. Inclusion signals to researchers that a journal has met internationally recognized standards of quality and that its articles will be discoverable, citable, and counted in the citation networks that shape modern scientific communication.

The timing of the journal’s admission matters as well. Coverage beginning in 2021 means that articles published from that year onward are tracked in the index, allowing citations to accumulate and, after the standard waiting period, contributing to the Impact Factor calculations released annually. The 2022 Impact Factor of 5.5 reflects the frequency with which articles published in 2020 and 2021 were cited during 2022, normalized across the number of substantive research items the journal published in that window. A value of 5.5 is a strong result in pharmacology, a field where citation patterns are often concentrated in a small number of high-profile journals. Reaching a figure of this magnitude shortly after entering the index is notable, because new entrants typically take several years to build the citation base needed for competitive Impact Factors.

Equally significant is the journal’s position within its category. The Web of Science ranks journals in each subject category both by raw Impact Factor and by percentile, dividing them into quartiles designated Q1 through Q4. Ranking 48th out of 278 journals in Pharmacology and Pharmacy places the Journal of Pharmaceutical Investigation in Q1, the top quartile, roughly the top 17 percent of journals in the category. Many universities, funding agencies, and research assessment exercises treat Q1 status as a benchmark of excellence, and publishing in Q1 journals can influence hiring decisions, grant evaluations, and institutional rankings. For authors weighing where to submit their work, the combination of indexing, a healthy Impact Factor, and Q1 ranking makes the journal a considerably more attractive destination than it was before these achievements.

The mechanics behind these numbers deserve a closer look, because they illuminate how scientific reputation is quantified. The Impact Factor, despite its limitations and the ongoing debate about the role it should play in research assessment, remains the single most requested journal metric worldwide. It is computed by dividing the number of citations in a given year to items published in the journal during the preceding two years by the number of citable items, typically articles and reviews, published in those same two years. Distinguishing between citable and non-citable items, such as editorials, letters, and news pieces, is a frequent source of confusion and contention, but the underlying idea is straightforward: the metric aims to capture the average annual citation rate of a journal’s core scholarly output. A journal that publishes clinically and scientifically relevant work in drug development, formulation, pharmacokinetics, and therapeutic evaluation tends to attract steady citation attention from both academic and industry-affiliated researchers.

For the pharmaceutical research community specifically, the value of robust indexing extends beyond prestige metrics. Pharmaceutics and pharmacology are deeply interdisciplinary fields in which academic laboratories, hospital pharmacists, regulatory scientists, and industrial researchers all draw on the same literature. When a journal is comprehensively indexed in Science Citation Index Expanded, its articles become systematically searchable through Web of Science interfaces and through the many discovery platforms that build on its data. Systematic reviews, meta-analyses, and evidence syntheses, all of which are central to evidence-based pharmacotherapy, depend on comprehensive retrieval of relevant studies. Gaps in indexing can mean that important research is overlooked in these syntheses, so broad coverage benefits not just the journal but the accuracy and completeness of the scientific record as a whole.

The journal’s subject scope explains much of its appeal to contributors and readers. Publications of this kind typically cover investigations spanning drug delivery systems, pharmacokinetics and pharmacodynamics, clinical pharmacy practice, pharmaceutical technology, and therapeutic outcomes, providing a venue for work that bridges laboratory formulation science and clinical application. Research of this type sits at the intersection of chemistry, biology, medicine, and engineering, and its readership spans hospital pharmacies, academic departments of pharmaceutics, regulatory bodies, and pharmaceutical companies. A journal serving such a broad community has a strong incentive to maximize discoverability, since potential authors and readers are distributed across many countries and many professional settings. Indexing in the major citation databases is the most direct route to that visibility, and the Q1 ranking now makes the journal competitive for submissions that might previously have gone to longer-established titles.

It is also worth situating this achievement within broader trends in scholarly publishing. The pharmaceutical sciences have expanded dramatically over the past two decades, driven by biologics, novel drug delivery platforms, nanomedicine, and the growing importance of pharmacoeconomics and health outcomes research. This expansion has multiplied the number of journals competing for high-quality submissions, intensifying pressure on editors to demonstrate quality through metrics. At the same time, the research community and major funders have increasingly questioned overreliance on the Impact Factor, promoting alternatives such as article-level citation measures, preprint visibility, and responsible research assessment frameworks. Even so, indexing status and quartile rankings continue to function as practical gatekeepers in the day-to-day decisions of authors, librarians, and evaluators, which is why a journal’s successful entry into the Science Citation Index Expanded and its attainment of Q1 status remain genuinely newsworthy events for its community.

Looking ahead, the journal’s trajectory will depend on sustaining the editorial standards and citation performance that earned its current standing. Early Impact Factors can be volatile, and consolidating a Q1 position requires consistent publication of work that other researchers find useful and citable. If the journal maintains the quality and breadth that accompanied its 2021 indexing and its 2022 Impact Factor of 5.5, it is well positioned to strengthen its role as a reference point for pharmaceutical investigation internationally. For now, the combination of Science Citation Index Expanded coverage, a solid Impact Factor, and a top-quartile category ranking represents a clear vote of confidence from the bibliometric infrastructure that helps determine which journals the global research community reads, cites, and trusts.

Subject of Research: Abstracting and indexing of the Journal of Pharmaceutical Investigation in Science Citation Index Expanded and its 2022 Impact Factor of 5.5 with Q1 ranking in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, SciSearch, Web of Science, Impact Factor, Q1 journal, Pharmacology and Pharmacy, journal indexing, citation metrics, pharmaceutical sciences, Clarivate, scholarly publishing

The Science Citation Index Expanded, often encountered by researchers under its search interface name SciSearch or through the Web of Science platform, functions as a comprehensive record of scholarly articles across the natural sciences, engineering, and medicine. When a journal is accepted into the index, every published article receives structured metadata — authors, affiliations, abstracts, keywords, and references — that allows the paper to be retrieved, linked, and counted. Citations flowing between indexed journals form the raw material for a family of quantitative indicators, most famously the Journal Impact Factor, that have become embedded in hiring, funding, and institutional evaluation processes around the world. Absence from the index, by contrast, can leave even high-quality research effectively invisible to large portions of the international community, particularly automated literature-discovery systems and systematic review workflows that rely on indexed databases as their primary search universe.

Following its inclusion, the Journal of Pharmaceutical Investigation recorded a Journal Impact Factor of 5.5 for 2022, a figure derived from the ratio of citations received in that year to the citable items — typically original research articles and reviews — published during the preceding two-year window. In the subject category of Pharmacology and Pharmacy, that score corresponded to a ranking of 48th out of 278 indexed journals, placing the publication in the first quartile, or Q1, of its field. Quartile position is a compressed but influential signal: it indicates that a journal sits among the top quarter of titles in its discipline by citation density, and many institutions explicitly require Q1 placement when researchers select venues for their work. For a journal that had operated for years outside the indexed core, the debut performance represents an unusually strong entry.

The mechanics behind these numbers are worth unpacking, because they explain both the value and the limitations of the metric. An impact factor of 5.5 means that, on average, each citable item published by the journal in 2020 and 2021 was cited 5.5 times in 2022 across the entire indexed literature. Review articles, which synthesize large bodies of work and are cited heavily, can inflate this average; so can a small number of highly cited papers in a small publication volume. Journal size, publication frequency, and topical timing all introduce volatility, which is why bibliometric experts consistently caution against treating the impact factor as a direct measure of the quality of any individual paper. A citation to a specific article is a vote for that article’s usefulness, not for every article sharing the same masthead. Nevertheless, at the level of journal selection — deciding where to submit, which subscriptions to fund, or which titles to trust for rapid scanning — the metric retains enormous practical weight, and a Q1 ranking in a competitive category such as Pharmacology and Pharmacy, where 278 titles compete, signals genuine traction with the research community.

The context in which this achievement occurred matters as much as the number itself. Pharmaceutical investigation as a discipline sits at a crowded crossroads: medicinal chemistry, pharmacokinetics, drug delivery, clinical pharmacology, and regulatory science all generate vast literatures, and hundreds of journals compete for the manuscripts that result. In such an environment, visibility is a scarce resource. Authors increasingly consult journal metrics before submitting, and funding agencies in many countries now ask applicants to characterize the venues in which their prior work appeared. A journal’s entry into the Science Citation Index Expanded therefore changes its competitive position in a feedback loop that can accelerate over successive years: indexing brings discoverability, discoverability brings readers and citations, citations bring higher metrics, and higher metrics attract stronger submissions, which in turn reinforce the citation profile. Editorial teams are well aware of this dynamic, which is why indexing milestones are often described within the publishing industry as inflection points rather than endpoints.

For the research community in pharmaceutical science, the practical consequences of indexing are concrete. A scientist in Seoul, São Paulo, or Stockholm running a structured literature search through Web of Science will now surface relevant articles from the journal that previously would have been missed by that particular query, even if they were retrievable through other services such as PubMed or Scopus. Systematic reviewers, who follow strict protocols requiring multi-database searching to avoid bias, can now legitimately include the journal in their source lists. Bibliometric analysts mapping collaboration networks or tracking research fronts in drug development will find its citation links woven into their datasets. Even citation managers and reference-checking tools benefit, because indexed metadata is typically cleaner and more complete than the free-text records scraped from journal websites. In short, indexing converts a journal from an isolated island of content into a node in the interconnected graph of global scholarship.

The milestone also reflects broader changes in how scholarly publishing evaluates and rewards journals. The Science Citation Index Expanded has tightened its acceptance criteria over the past decade, applying a consistent editorial standards review that examines publication ethics, peer-review rigor, editorial board composition, timeliness, and international authorship alongside raw citation performance. Journals are no longer admitted simply because they publish frequently; they must demonstrate sustainable editorial governance and adherence to the community’s ethical norms. Achieving inclusion in the 2021 cycle therefore implies that the journal passed a substantive vetting process covering both its operational practices and the scientific standing of its published content. This dual scrutiny is one reason why indexing status carries credibility with institutions that must make funding and promotion decisions without reading every paper themselves.

At the same time, the pharmaceutical sciences are undergoing a transformation that gives journals in this field unusual strategic importance. The past several years have seen unprecedented attention to drug development — from the rapid clinical evaluation of vaccines and antivirals to the rise of biologics, mRNA platforms, and precision medicine approaches tailored to molecular subtypes of disease. Each of these frontiers generates intense publication activity, and the citation metrics of journals in Pharmacology and Pharmacy have shifted accordingly, with the field’s leading titles posting some of the strongest citation growth in the biomedical sciences. A journal entering the indexed landscape during such a period inherits both opportunity and pressure: the appetite for pharmaceutical research findings is enormous, but so is the competition, and new entrants must quickly establish editorial identity — whether in translational pharmacology, formulation science, or clinical investigation — to convert visibility into durable citation performance.

Looking ahead, the trajectory of the journal will depend on factors that no single metric can fully capture. Sustaining a Q1 position requires consistent editorial output, successful attraction of high-impact submissions, and continued adherence to the standards that secured indexing in the first place. Citation databases conduct periodic re-evaluation, and titles that slip in quality or timeliness can be discontinued from coverage, a risk that keeps editorial offices accountable long after the initial acceptance. For now, however, the combination of Science Citation Index Expanded coverage and a first-quartile impact factor of 5.5 gives the Journal of Pharmaceutical Investigation the visibility infrastructure and quantitative credentials that authors, reviewers, and readers in the global pharmaceutical research community rely upon when deciding where the most consequential work in their field is being published and debated.

Subject of Research: Abstracting and indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its Q1 impact factor in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, Journal Impact Factor, pharmacology and pharmacy, Q1 journal ranking, abstracting and indexing, Web of Science, bibliometrics, scholarly publishing, pharmaceutical sciences, citation metrics, Clarivate Analytics

Abstracting and indexing is the process by which a journal’s published articles are systematically catalogued in major bibliographic databases, allowing them to be discovered, cited, and tracked by the global research community. Inclusion in the Science Citation Index Expanded, one of the core citation databases maintained within the Web of Science platform, signals that a journal has passed a rigorous editorial evaluation covering publishing standards, editorial board composition, peer-review integrity, international diversity of authorship, and the consistency of its scholarly output. For pharmaceutical researchers, this means that articles appearing in the journal are now fully searchable alongside the most influential literature in pharmacology and pharmacy, and that citations to those articles are counted in official journal metrics.

The Impact Factor, the most widely recognized of these metrics, is calculated by dividing the number of citations received in a given year by articles published in the two preceding years. A value of 5.5 for 2022 indicates that, on average, papers published in the journal during 2020 and 2021 were cited 5.5 times in 2022. This figure places the journal comfortably within the upper tier of its category, since quartile rankings divide the journals in a subject class into four equal groups by citation performance. A Q1 designation, corresponding to the top 25 percent of the 278 journals ranked in Pharmacology and Pharmacy, is a benchmark many institutions use when assessing publication quality for hiring, promotion, and funding decisions.

The rank of 48 out of 278 is particularly notable in a category as large and competitive as Pharmacology and Pharmacy, which spans everything from basic molecular pharmacology to clinical therapeutics and pharmaceutical manufacturing. Journals in this category compete for citations from a vast body of global research, and moving into the first quartile typically requires sustained growth in both the quality and the visibility of published work. For a journal focused specifically on pharmaceutical investigation, the achievement reflects the growing citation footprint of research on drug delivery systems, nanomedicine, pharmacokinetics, and the formulation technologies that translate laboratory discoveries into clinical products.

Indexing in SciSearch since 2021 means the journal’s metrics are still relatively young within the Web of Science ecosystem, which makes the 2022 Impact Factor an early but meaningful indicator of its trajectory. New journals often take several years to accumulate the citation history needed for stable rankings, and early Impact Factors can fluctuate as the indexed back-file grows. A first-quartile placement within roughly two years of indexing suggests that the journal’s existing body of work was already attracting substantial citations, and that its inclusion in the database made that influence visible to the evaluators, librarians, and researchers who rely on these metrics to navigate the literature.

The practical consequences of indexing and quartile performance extend well beyond prestige. Researchers choosing where to submit manuscripts frequently consult journal rankings to maximize the reach and career value of their work, and many funding agencies and universities maintain lists of approved outlets based on Web of Science categories and quartiles. Librarians use the same data to make subscription decisions. For authors in pharmaceutical sciences, a Q1 journal with a 5.5 Impact Factor offers a combination of disciplinary focus and broad discoverability that can accelerate the uptake of new methods, from controlled-release formulations to novel excipients and biopharmaceutical characterization techniques.

Bibliometric experts caution, however, that the Impact Factor is a blunt instrument. It measures average citations to a two-year window of articles and can be influenced by a small number of highly cited reviews, by the overall volume of publication, and by citation practices that vary across subfields. Pharmacology and pharmacy journals, which sit at the interface of basic science and applied medicine, often benefit from citation patterns that differ from those of purely clinical or purely basic titles. For this reason, evaluators are increasingly encouraged to read quartile rankings alongside other indicators, such as the journal’s scope, its peer-review standards, and the actual readership of individual papers rather than journal-level averages alone.

Even with those caveats, the formal recognition matters for the research community the journal serves. Pharmaceutical investigation is a field in which translational timelines are long and the path from molecular discovery to approved therapy depends on shared methodological standards. When a specialized journal achieves first-quartile status, it strengthens the visibility of the applied and formulation-oriented research that often falls between the traditional categories of pharmacology and chemical engineering. This can help ensure that advances in drug delivery technology, bioequivalence assessment, and pharmaceutical quality control receive the same citation attention as breakthroughs in target discovery or clinical trial results.

The journal’s listing with Springer, which publishes the title as part of its pharmaceutical sciences portfolio, provides the authoritative record of its indexing status and metric performance. The publisher’s announcement confirms both the 2021 start of Science Citation Index Expanded coverage and the 2022 Impact Factor of 5.5, along with the category rank of 48 out of 278 in Pharmacology and Pharmacy. These figures will be updated annually as new citation data become available, and the journal’s position will be watched by authors, editors, and bibliometric analysts alike as an indicator of how specialized pharmaceutical research titles fare in an increasingly metrics-driven publishing environment.

For the broader scientific publishing landscape, the case illustrates how abstracting and indexing functions as the gateway through which journals enter the formal economy of scholarly recognition. Without inclusion in the major citation databases, even high-quality research risks invisibility in the evaluations that shape careers and funding. With inclusion, and with a strong early Impact Factor, a journal can rapidly become a destination for the work that defines its field. The Journal of Pharmaceutical Investigation’s Q1 standing demonstrates that a focused pharmaceutical title can achieve that recognition quickly, provided its published research resonates with the citation behavior of the international pharmacology and pharmacy community.

Subject of Research: Indexing of the Journal of Pharmaceutical Investigation in Science Citation Index Expanded and its 2022 Impact Factor of 5.5 with a Q1 rank of 48/278 in Pharmacology and Pharmacy

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Impact Factor, quartile ranking, pharmacology and pharmacy, Web of Science, bibliometrics, pharmaceutical sciences, Springer, citation metrics

Abstracting and indexing services form the backbone of scientific communication infrastructure. When a journal is abstracted and indexed, its article records, including titles, author names, affiliations, abstracts and bibliographies, are systematically captured and catalogued in large bibliographic databases that researchers around the world use every day. Science Citation Index Expanded, maintained within the Web of Science platform, is one of the most selective and widely consulted of these services. Inclusion signals that a journal has passed editorial quality assessments covering peer-review rigor, publication ethics, editorial board composition, timeliness and international reach. For a pharmaceutical sciences journal, this recognition is particularly consequential because the field spans chemistry, pharmacology, formulation science, clinical investigation and regulatory science, and its researchers rely on comprehensive literature discovery to avoid duplication and build on prior findings.

The mechanics of indexing are less visible to readers but essential to how science circulates. Once a journal is accepted into SciSearch, every published article receives consistent metadata treatment: digital object identifiers are registered, citations between articles are tracked, and bibliometric algorithms can count how often a paper is referenced by later work. This citation network is what makes quantitative measures possible in the first place. Without structured indexing, citation counts would be fragmented across publisher websites and impossible to aggregate reliably. Indexed status also enables discovery through search platforms that institutions license, meaning a clinical pharmacist in Seoul or a formulation scientist in Boston encounters the journal’s content through the same trusted databases rather than through scattered web searches.

The impact factor of 5.5 reported for 2022 is calculated through a well-defined formula: it counts the citations received in that year by articles the journal published in the two preceding years, divided by the number of citable items, typically research articles and reviews, published in those same two years. A value of 5.5 means that, on average, recent articles in the journal were cited more than five times within roughly two years of publication, a strong performance in pharmacology and pharmacy, where citation patterns tend to be steadier and more gradual than in fast-moving fields such as molecular biology. The Q1 designation, derived from the journal’s position at 48 of 278 in its category, means it falls within the top quartile of titles, a threshold many institutions use as a benchmark for high-quality publication.

Within the pharmaceutical research community, these metrics carry practical weight. Journals that rank highly attract manuscripts from established laboratories, which in turn raises the technical quality and relevance of published work, creating a feedback loop of visibility and citation. For authors, publishing in an indexed, Q1-ranked journal ensures that their findings are counted in institutional assessments, grant applications and national research evaluation frameworks, many of which explicitly require Web of Science or Scopus inclusion. For readers, the ranking acts as a quality heuristic, a signal that the peer review process has historically filtered submissions with reasonable strictness. For librarians managing tight budgets, category rank and impact factor often inform subscription and renewal decisions, so a journal’s bibliometric performance directly shapes whether researchers can access it at all.

The journal’s subject area itself explains why this recognition resonates. Pharmaceutical investigation encompasses preclinical drug evaluation, pharmacokinetics and pharmacodynamics, novel delivery systems, nanotechnology-based formulations, biopharmaceutics and translational research linking laboratory findings to clinical outcomes. This is a domain where the pace of innovation is accelerating, driven by biologics, RNA therapeutics, targeted delivery platforms and computational drug design. Researchers in these areas depend on rapid, reliable access to peer-reviewed results, and a journal embedded in the core citation indexes effectively becomes part of the discipline’s shared memory. Articles that might otherwise remain niche become discoverable through citation chains, review articles and database alerts.

Entry into Science Citation Index Expanded in 2021 marked a milestone because that year is the starting point from which the journal’s citation record accumulates in the index. Impact factors for newly indexed journals require a lag period before the citation window contains sufficient data, so the 5.5 figure for 2022 represents the first full measurement of the journal’s citation performance within the service. Achieving a Q1 rank in that early measurement window is notable, since it indicates that work published in the journal was already being cited at a level competitive with long-established titles in pharmacology and pharmacy. It also suggests that the journal’s editorial scope aligns with active research fronts where citation activity is naturally concentrated.

Bibliometric indicators should nevertheless be read with nuance, a point widely acknowledged across the scholarly communication community. An impact factor describes the average citation behavior of a journal’s recent output, not the quality of any individual article, and citation counts vary by article type, topic popularity and review share. A journal publishing influential methodological reviews may see its average lifted relative to one focused on narrow empirical studies. Category rankings are more robust because they compare journals within the same discipline, but they still aggregate across subfields with different citation customs. Researchers and evaluators are therefore encouraged to treat the 5.5 impact factor and Q1 rank as one signal among several, alongside peer review reports, replication records and the actual content of the research itself.

For the journal’s editorial team, sustained indexing brings ongoing obligations. Indexed journals must maintain consistent publication schedules, transparent peer review workflows, correctable article records and adherence to publishing ethics standards. Data integrity, authorship transparency and conflict-of-interest disclosure are scrutinized both at submission and in periodic re-evaluation by indexing services, which can delist journals that fall short. This accountability framework benefits the entire pharmaceutical sciences community: it keeps the citation record trustworthy, ensures that meta-analyses and systematic reviews rest on verifiable sources, and protects early-career researchers who stake their careers on publications whose provenance must withstand institutional scrutiny.

As pharmaceutical research grows more interdisciplinary, the role of well-indexed journals as connective tissue between chemistry, biology, engineering and clinical medicine will only expand. The Journal of Pharmaceutical Investigation’s presence in Science Citation Index Expanded since 2021, combined with its 2022 impact factor of 5.5 and its Q1 standing at 48 of 278 in Pharmacology and Pharmacy, positions it as a reference point for researchers navigating this crowded landscape. Whether these metrics translate into durable scientific influence depends on the quality of the work the journal continues to publish and the rigor of its editorial processes, but the early indicators suggest that its articles are reaching the audiences positioned to build on them, cite them and, ultimately, convert them into better medicines.

Subject of Research: Abstracting, indexing and citation performance of the Journal of Pharmaceutical Investigation in Web of Science and pharmacology journal rankings

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, abstracting and indexing, Science Citation Index Expanded, SciSearch, Web of Science, impact factor, Q1 journal, Pharmacology and Pharmacy, pharmaceutical sciences, bibliometrics, scholarly publishing, citation metrics

To understand why this matters, it helps to unpack what abstracting and indexing actually involves. Abstracting services capture the summary, or abstract, of each article along with its metadata: authors, affiliations, keywords and journal details. Indexing goes a step further, embedding that metadata into structured databases that can be searched, cross-referenced and analyzed at scale. The Science Citation Index Expanded, maintained by Clarivate as part of the Web of Science Core Collection, is among the most selective of these databases. Journals are admitted only after an editorial evaluation that examines editorial rigor, peer-review integrity, the international diversity of authorship, regularity of publication and the citation behavior of the published content. Once a journal is accepted, every article it publishes is ingested, its reference list is parsed, and each cited reference is linked to the database’s network of scholarly records.

That reference linking is what makes citation metrics possible. When a paper published in the Journal of Pharmaceutical Investigation is cited by a researcher anywhere in the indexed literature, the event is recorded, timestamped and attributed. Aggregated over time, these events feed the Journal Impact Factor, a metric calculated annually in Clarivate’s Journal Citation Reports. The formula is deceptively simple: the 2022 impact factor counts citations made in 2022 to items the journal published in 2020 and 2021, divided by the number of citable items, typically articles and reviews, published in those same two years. A score of 5.5 therefore means that, on average, each citable paper from the journal’s 2020 and 2021 volumes was cited 5.5 times in the following year by the indexed literature.

The category ranking adds a second layer of interpretation. Pharmacology and Pharmacy is one of the largest and most competitive categories in the Journal Citation Reports, containing 278 journals that range from basic molecular pharmacology to clinical therapeutics and formulation science. Ranking 48th in that field places the journal in the 17th percentile, comfortably inside the Q1 quartile that spans the top 25 percent of titles. Quartile assignments matter in practical academic life: hiring committees, grant agencies and national evaluation systems in many countries use Q1 status as a shorthand for journal prestige, and some funding bodies explicitly require that publications appear in Q1 or Q2 journals to count toward a researcher’s track record.

For a journal focused on pharmaceutical investigation, the indexing milestone also changes how its content circulates. Articles in the Science Citation Index Expanded are surfaced through Web of Science searches used daily by millions of researchers, and the indexed metadata feeds into citation alerts, research profiles and institutional dashboards. Downstream services, including citation managers, discovery layers at university libraries and literature-screening tools used in drug-safety reviews, draw on the same structured records. In practical terms, a pharmacokinetics study or a novel drug-delivery paper published in the journal is now far more likely to be found, cited and built upon by teams working in formulation chemistry, clinical pharmacy and regulatory science around the world.

The timing is notable against the backdrop of a broader debate about how scientific quality should be measured. The impact factor, conceived in the 1960s as a tool for librarians deciding which journals to subscribe to, has become one of the most scrutinized numbers in science. Critics, including the signatories of the San Francisco Declaration on Research Assessment, argue that the metric is easily skewed by a small number of highly cited papers, that it differs across fields in ways that make cross-disciplinary comparisons misleading, and that it says nothing about the quality of any individual article. Defenders counter that, for all its flaws, the impact factor remains a transparent, reproducible and widely understood indicator of a journal’s average citation performance, and that quartile rankings within a single field, such as Pharmacology and Pharmacy, offer a fairer like-for-like comparison.

Clarivate itself has been evolving the ecosystem around these metrics. In recent years the Journal Citation Reports have added supplementary indicators, including the Journal Impact Factor percentile, the five-year impact factor and the Eigenfactor-style measures that weight citations by the prestige of the citing journal. The 2023 release extended impact factors to all journals in the Web of Science Core Collection, including those in the Emerging Sources Citation Index, a change that increased the number of titles receiving the metric from roughly 9,500 to more than 21,000. For newly indexed journals, this expansion means that citation performance is visible almost immediately after entry into the collection, rather than after the traditional multi-year waiting period, accelerating the feedback loop between publication and measurable scholarly impact.

Behind the headline numbers lies a labor-intensive editorial operation. Journals seeking Science Citation Index Expanded inclusion must demonstrate consistent publication schedules, robust peer-review processes, ethical publishing practices aligned with guidelines from the Committee on Publication Ethics, and content that is genuinely international in authorship and readership. Clarivate’s editorial development team also assesses whether the journal fills a distinctive niche relative to existing coverage, a criterion that rewards publications addressing specific research communities, such as pharmaceutical formulation, biopharmaceutics and translational drug research, rather than duplicating well-served areas. Once admitted, journals remain under continuous review, and titles whose quality or citation performance deteriorates can be flagged or delisted, a mechanism that has drawn increased attention as the publishing industry confronts paper mills and predatory outlets.

For researchers deciding where to submit their work, the combination of Q1 status and a 5.5 impact factor signals that the journal now competes directly with established titles in pharmaceutical science. Authors in drug delivery and pharmaceutical technology often weigh several factors beyond the impact factor: the speed of peer review, open-access options and licensing terms, the journal’s readership among industrial and regulatory scientists, and how quickly an accepted paper becomes visible in indexing services. Full indexing in the Science Citation Index Expanded addresses the visibility component decisively, since every accepted article enters the citation network from the point of indexing onward, accumulating the references that will determine future metric cycles.

The broader lesson from the journal’s trajectory is that scholarly visibility is built in layers: rigorous peer review attracts strong papers, strong papers attract citations, citations drive impact factors, and impact factors, in turn, attract more strong submissions. Indexing in the Science Citation Index Expanded is the infrastructure that makes this cycle measurable. As the 2023 and 2024 publication years accumulate citations, the journal’s position within the Pharmacology and Pharmacy rankings will be tested against 277 competitors, many of them far larger and longer-established. Whether it consolidates its Q1 standing or climbs higher, its entry into the citation mainstream marks the moment when its research output became fully countable in the quantitative machinery that increasingly shapes careers, funding decisions and the global flow of pharmaceutical science.

Subject of Research: Abstracting and indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its Q1 impact factor ranking in pharmacology

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, Web of Science, Journal Impact Factor, Clarivate, Q1 journal, Pharmacology and Pharmacy, citation analysis, abstracting and indexing, pharmaceutical science, research metrics, peer review